This is a Phase III news story, published by Ars Technica, that relates primarily to Hoau-Yan Wang news.
For more Phase III news, you can click here:
more Phase III newsFor more Hoau-Yan Wang news, you can click here:
more Hoau-Yan Wang newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
pharmaceutical company Cassava Sciences. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest embattled Alzheimer news, simufilam trial news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
controversial AlzheimerArs Technica
•90% Informative
Hoau-Yan Wang , 67 , is accused of falsifying data to obtain $16 million in federal funding.
Wang 's research provided scientific underpinnings for Cassava 's Alzheimer's treatment, Simufilam , which is now in Phase III trials.
Wang is charged with one count of major fraud against the United States , two counts of wire fraud, and one of false statements.
VR Score
93
Informative language
93
Neutral language
66
Article tone
formal
Language
English
Language complexity
69
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
10
Source diversity
8
Affiliate links
no affiliate links